These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25370457)

  • 1. Microsomal triglyceride transfer protein inhibition: a novel treatment for lowering plasma cholesterol.
    Das G; Rees A
    Curr Opin Lipidol; 2014 Dec; 25(6):471-3. PubMed ID: 25370457
    [No Abstract]   [Full Text] [Related]  

  • 2. Microsomal transfer protein inhibition in humans.
    Cuchel M; Rader DJ
    Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.
    Cuchel M; Bloedon LT; Szapary PO; Kolansky DM; Wolfe ML; Sarkis A; Millar JS; Ikewaki K; Siegelman ES; Gregg RE; Rader DJ
    N Engl J Med; 2007 Jan; 356(2):148-56. PubMed ID: 17215532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
    Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
    Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
    Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
    Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia.
    Raper A; Kolansky DM; Sachais BS; Meagher EA; Baer AL; Cuchel M
    J Clin Lipidol; 2015; 9(1):107-12. PubMed ID: 25670368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lomitapide.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):179-81. PubMed ID: 25702706
    [No Abstract]   [Full Text] [Related]  

  • 9. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder.
    Smith RJ; Hiatt WR
    JAMA Intern Med; 2013 Sep; 173(16):1491-2. PubMed ID: 23649296
    [No Abstract]   [Full Text] [Related]  

  • 10. [Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B].
    Alonso R; Mata P; Alonso Y Gregorio M; de Andrés R
    Med Clin (Barc); 2015 Sep; 145(5):229-30. PubMed ID: 25543225
    [No Abstract]   [Full Text] [Related]  

  • 11. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.
    Toth PP; Shah PK; Wilkinson MJ; Davidson MH; McCullough PA
    Rev Cardiovasc Med; 2014; 15(1):1-10. PubMed ID: 24762461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering treatment for homozygous familial hypercholesterolaemia.
    Santos RD
    Lancet; 2013 Apr; 381(9873):1182. PubMed ID: 23561997
    [No Abstract]   [Full Text] [Related]  

  • 14. Familial hypercholesterolemia.
    Hegele RA
    N Engl J Med; 2007 Apr; 356(17):1779; author reply 1779-80. PubMed ID: 17460234
    [No Abstract]   [Full Text] [Related]  

  • 15. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
    Roeters van Lennep J; Averna M; Alonso R
    J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol lowering and ezetimibe.
    Drazen JM; Jarcho JA; Morrissey S; Curfman GD
    N Engl J Med; 2008 Apr; 358(14):1507-8. PubMed ID: 18376001
    [No Abstract]   [Full Text] [Related]  

  • 17. Lomitapide.
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):347-52. PubMed ID: 21846156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?
    Brown BG; Taylor AJ
    N Engl J Med; 2008 Apr; 358(14):1504-7. PubMed ID: 18376002
    [No Abstract]   [Full Text] [Related]  

  • 19. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
    Perry CM
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors.
    Robl JA; Sulsky R; Sun CQ; Simpkins LM; Wang T; Dickson JK; Chen Y; Magnin DR; Taunk P; Slusarchyk WA; Biller SA; Lan SJ; Connolly F; Kunselman LK; Sabrah T; Jamil H; Gordon D; Harrity TW; Wetterau JR
    J Med Chem; 2001 Mar; 44(6):851-6. PubMed ID: 11300866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.